Rafferty Asset Management
CARM

Rafferty Asset Management’s Carisma Therapeutics CARM Stock Holding History

Rafferty Asset Management’s Portfolio CARM Stock Details CARM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-1,455
Closed -$23K – 1301
2021
Q3 		$23K Sell
1,455
-29,233
-95% -$1.4M ﹤0.01% 1251
2021
Q2 		$2.84M Buy
+30,688
New +$1.96M 0.02% 524

Other funds holding CARM

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Prudential Financial
Prudential Financial Newark, New Jersey $81.2B AUM 27.81% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Rafferty Asset Management's CARM Position: Q4 2021 in Review

Rafferty Asset Management sold out of Carisma Therapeutics (CARM) in Q4 2021, closing a stake of 1,455 shares — an estimated $23K sold.

Rafferty Asset Management first reported a position in CARM in Q2 2021 and held it in 2 quarters. The position peaked at $2.84M in Q2 2021. 93 funds tracked by Wall St. Rank hold CARM as of Q4 2021.

  • Rafferty Asset Management reported no remaining Carisma Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Rafferty Asset Management sold 1,455 Carisma Therapeutics shares in Q4 2021, an estimated $23K.
  • Rafferty Asset Management first reported a position in Carisma Therapeutics in Q2 2021 and held it in 2 quarters.
  • Rafferty Asset Management's Carisma Therapeutics position peaked at $2.84M in Q2 2021.
  • 93 funds tracked by Wall St. Rank held Carisma Therapeutics as of Q4 2021.

Based on Rafferty Asset Management's 13F filing for Q4 2021, filed 10 Feb 2022.